Business programme

To achieve national pharmaceutical security, countries need to reduce their critical reliance on imported active pharmaceutical ingredients (APIs). Many of the APIs needed to manufacture medicinal products in Russia currently originate abroad, which jeopardizes the stability of supplies and limits the industry’s sovereignty. Today, the pharmaceutical sector faces the challenge of synchronizing scientific, manufacturing, and regulatory solutions in order to achieve the objectives contained in the Strategy for the Development of the Pharmaceutical Industry of the Russian Federation until 2030. As part of this process, it is crucial to both reduce dependence on imported APIs for the production of generic medicines as well as create an innovation-friendly environment in which new medicinal products cannot be developed without the required expertise and experience in creating and manufacturing pharmaceutical APIs. Which state regulatory measures are most effective in supporting API manufacturers? How quickly will the range of medicinal products manufactured using domestic APIs be expanded and based on what criteria? What level of localization is required in terms of technological processing stages (sequential steps of chemical synthesis) for a substance to be granted domestic status?

Born on March 15, 1973 in Jaipur, India. Russian citizen.
Graduated from Birla High School in Pilani. In 1992 started his higher education in Russia, at Irkutsk State Medical University. Later graduated from the Far Eastern Federal University, majoring in Finance and Credit. Married, with three children.
Founder of Pharmasyntez, member of the Leaders’ Club to Promote Business Initiatives (a non-profit partnership), Co-Chairman of the Business Council for Cooperation with India, participant in several investment forums and business missions.
Pharmasyntez manufactures medicinal drugs for socially significant diseases, such as tuberculosis, HIV/AIDS, cancer, hepatitis and diabetes. The company’s profile includes over 113 various pharmaceutical forms and dosages – caps, pills, granules, IV solutions, sterile dry powders, solutions for injection and lyophilisates. Currently Pharmasyntez has five GMP compliant manufacturing facilities in the following Russian cities: Saint Petersburg, Tyumen, Bratsk, Irkutsk and Ussuriysk. The company employs over 1500 qualified specialists.
Pharmasyntez was number one Russian pharmaceutical manufacturer based on hospital purchases in 2016 (and No. 5 out of all pharmaceutical manufacturers, based on hospital purchases records). In 2016 it also became the fastest growing Russian manufacturing company with the revenue of 12 billion, which has doubled in comparison with 2014.
Currently Pharmasyntez is Russia’s leader in manufacturing medicinal agents for tuberculosis, retrovirus and cancer. Farmasintez does innovative R&D and exports pharmaceutical agents from Russia. The company is Irkutsk’s biggest tax payer.

Born in 1978 in Leningrad.
Education: School of Economics, St. Petersburg State University; internship at Yale University, USA, in 1995–1996.
Pytr Rodionov became the CEO of GEROPHARM in 2001. Under his leadership, the company stepped up to be an efficient business entity and a major player in Russia’s pharmaceutical market, as well as a recognized expert in the professional community.
In 2013–2017 Pyor Rodionov received the Chief of the Year award and the Expert of the Year title (from Expert North-West magazine), entered TOP 250 of Russia’s CEOs and won the Entrepreneur of the Year award (EY) and RBC Award (St. Petersburg).
Pyotr Rodionov is a member of Delovaya Rossiya All Russia Public Organization, Council on Guardianship under the Government of the Russian Federation and Subcommittee on circulation of medicines under the Commission on Healthcare of the Government of the Russian Federation. In 2016 he joined State Duma Committee for biotechnology, pharmaceutical and medical industry, as well as Social and Business Council of the Healthcare Strategic Development Project under the Government of the Russian Federation.

Alexander Semenov has been working for the benefit of the pharmaceutical industry for more than 25 years, under his professional leadership, in October 2020, Active Component JSC concluded a special investment contract (SPIC) with St. Petersburg and the Ministry of Industry and Trade of the Russian Federation, and in December 2020, with the participation of officials of the Government of the Russian Federation, launched the 1st stage of the second production site of chemical pharmaceutical substances, most of which were not previously produced in Russia. Currently, the Company's portfolio includes over 60 INN substances for the most popular and socially significant medicines. Thanks to personal participation, strategic thinking and deep involvement of Alexander Semenov in management processes, Active Component is constantly increasing its production portfolio, the number of its own unique developments, the volume of products and creates new jobs. Through its activities, the Company contributes to the prosperity of the region, strengthening the national security of the country and reducing dependence on imported drugs, which served as its inclusion in the federal register of system-forming enterprises. Alexander was awarded the Gratitude of the Governor of St. Petersburg and is the winner of the "TOP CEO of 2021" competition according to Kommersant, is happily married and has four children.

Betting on Substance: Full-Cycle Technology Platforms as a Matter of Pharmaceutical Sovereignty

Moderator

Speakers

Broadcast

Apply to participate

Dmitry Galkin

Ivan Dratsky

Valentina Kosenko

Vikram Punia

Petr Rodionov

Filipp Romanov

Aleksandr Semenov

Dmitry Somov

Huang Xiaofei

Lyudmila Scherbakova